Naveen S. Basappa

2.0k total citations
98 papers, 830 citations indexed

About

Naveen S. Basappa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Naveen S. Basappa has authored 98 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Pulmonary and Respiratory Medicine, 45 papers in Oncology and 34 papers in Cancer Research. Recurrent topics in Naveen S. Basappa's work include Renal cell carcinoma treatment (64 papers), Cancer Genomics and Diagnostics (33 papers) and Renal and related cancers (26 papers). Naveen S. Basappa is often cited by papers focused on Renal cell carcinoma treatment (64 papers), Cancer Genomics and Diagnostics (33 papers) and Renal and related cancers (26 papers). Naveen S. Basappa collaborates with scholars based in Canada, United States and Japan. Naveen S. Basappa's co-authors include Lori Wood, Christian Kollmannsberger, Daniel Y.C. Heng, Anil Kapoor, Quincy S. Chu, Michael Smylie, Denis Soulières, Georg A. Bjarnason, Aly‐Khan A. Lalani and Toni K. Choueiri and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Naveen S. Basappa

90 papers receiving 818 citations

Peers

Naveen S. Basappa

PRM

ONCOL

SURGE

Azeem Mohammed United States

Sabrina H. Rossi United Kingdom

Martin Smoragiewicz Canada

Zbyněk Bortlíček Czechia

Toshiki Masuishi Japan

Christian Lerchenmüller Germany

Lina Yin China

Victoria Neiman Israel

Cinzia Ortega Italy

Suzanne Kosmider Australia

Azeem Mohammed United States

Naveen S. Basappa

560 ×0.9

PRM

204 ×0.6

ONCOL

364 ×1.1

169 ×0.8

111 ×0.8

SURGE

Citations per year, relative to Naveen S. Basappa Naveen S. Basappa (= 1×) peers Azeem Mohammed

Countries citing papers authored by Naveen S. Basappa

Since Specialization

Citations

This map shows the geographic impact of Naveen S. Basappa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naveen S. Basappa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naveen S. Basappa more than expected).

Fields of papers citing papers by Naveen S. Basappa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naveen S. Basappa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naveen S. Basappa. The network helps show where Naveen S. Basappa may publish in the future.

Co-authorship network of co-authors of Naveen S. Basappa

This figure shows the co-authorship network connecting the top 25 collaborators of Naveen S. Basappa. A scholar is included among the top collaborators of Naveen S. Basappa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naveen S. Basappa. Naveen S. Basappa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghosh, Sunita, Lori Wood, C. Kollmannsberger, et al.. (2025). Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients. Cancers. 17(3). 522–522. 2 indexed citations

Hamilou, Zineb, Sunita Ghosh, Daniel Yick Chin Heng, et al.. (2025). Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma. The Oncologist. 30(9). 1 indexed citations

Tanguay, Simon, Lori Wood, C. Kollmannsberger, et al.. (2025). Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study. Clinical Genitourinary Cancer. 23(3). 102342–102342. 1 indexed citations

Füzéry, Anna K., Joshua E. Raizman, Albert K.Y. Tsui, et al.. (2024). Elevated Troponin T in Immune-Checkpoint Inhibitor Myositis. JACC Case Reports. 29(16). 102462–102462. 1 indexed citations

Saad, Eddy, Georges Gebrael, Renée Maria Saliby, et al.. (2024). Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. The Oncologist. 29(8). 699–706.

Basappa, Naveen S., et al.. (2024). Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer. Current Oncology. 31(9). 5080–5087. 1 indexed citations

Graham, Jeffrey, Sunita Ghosh, Rodney H. Breau, et al.. (2024). Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis). Clinical Genitourinary Cancer. 22(3). 102060–102060.

Ghosh, Sunita, Lori Wood, Georg A. Bjarnason, et al.. (2024). Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database. Current Oncology. 31(8). 4704–4712. 3 indexed citations

Yip, Steven, Michael Kolinsky, Kosuke Takemura, et al.. (2023). 1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi). Annals of Oncology. 34. S972–S972. 1 indexed citations

10.

Ghosh, Sunita, Antonio Finelli, Lori Wood, et al.. (2023). Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System. JCO Global Oncology. 9(9). e2300271–e2300271. 1 indexed citations

11.

Schönlau, Elena, David C. Müller, Gillian Vandekerkhove, et al.. (2023). Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.. Journal of Clinical Oncology. 41(16_suppl). 4577–4577.

12.

Takemura, Kosuke, Naveen S. Basappa, Bernadett Szabados, et al.. (2023). Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology. 41(6_suppl). 600–600. 2 indexed citations

13.

Malone, Shawn, Christopher J.D. Wallis, Richard M. Lee‐Ying, et al.. (2022). Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study. SHILAP Revista de lepidopterología. 3(5). 383–391. 5 indexed citations

14.

Gan, Chun Loo, Igor Stukalin, Daniel E. Meyers, et al.. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 151. 115–125. 32 indexed citations

15.

Kushnir, Igal, Naveen S. Basappa, Sunita Ghosh, et al.. (2021). Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer. 19(6). 521–530. 12 indexed citations

16.

Basappa, Naveen S., Sunita Ghosh, Christian Kollmannsberger, et al.. (2021). Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer. 20(3). 210–218. 6 indexed citations

17.

Bhindi, Bimal, Jeffrey Graham, J. Connor Wells, et al.. (2020). Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology. 78(4). 615–623. 42 indexed citations

18.

Nayan, Madhur, Anil Kapoor, Antonio Finelli, et al.. (2019). Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic Oncology Seminars and Original Investigations. 37(9). 576.e11–576.e16. 2 indexed citations

19.

Malone, Shawn, Bobby Shayegan, Naveen S. Basappa, et al.. (2019). Management algorithms for metastatic prostate cancer. Canadian Urological Association Journal. 13(12). 50–60. 4 indexed citations

20.

Warren, Mark, Michael Kolinsky, Christina M. Canil, et al.. (2019). Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal. 13(10). 318–327. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact